Grifols
GRFS · NASDAQ
Bulios Fair Price
$8.63
17.4% upside
Current Price
$7.35
According to Bulios Fair Price, GRFS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Grifols, S.A. is a global Spanish pharmaceutical and biotechnology company specializing in the production of plasma-derived medicines and healthcare products. The company focuses on producing immunoglobulins, albumin, and other plasma-based products that are essential for the treatment of various diseases, including immunological and neurological disorders. Grifols also develops diagnostic tools and systems for hospitals and clinics. The company has a broad global presence and operates in over 30 countries worldwide.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Jose Ignacio Abia Buenache
Employees
25,258
Headquarters
Barcelona
Upcoming events
Earnings
Upcoming earnings report